Clinical Trial Update: Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating low-dose post-transplant cyclophosphamide after allogeneic stem cell transplantation to prevent graft-versus-host disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Status: RECRUITING